Related references
Note: Only part of the references are listed.Central Obesity and Multivariable Cardiovascular Risk as Assessed by the Framingham Prediction Scores
Satvinder S. Dhaliwal et al.
AMERICAN JOURNAL OF CARDIOLOGY (2009)
Reduction of dietary fat absorption by the novel gastrointestinal lipase inhibitor cetilistat in healthy volunteers
Andrew Bryson et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
The anorexic agents, sibutramine and fenfluramine, depress GABAB-induced inhibitory postsynaptic potentials in rat mesencephalic dopaminergic cells
Ada Ledonne et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
A Small Molecule That Blocks Fat Synthesis By Inhibiting the Activation of SREBP
Shinji Kamisuki et al.
CHEMISTRY & BIOLOGY (2009)
Endocannabinoids and Their Receptors as Targets for Obesity Therapy
Annette D. de Kloet et al.
ENDOCRINOLOGY (2009)
Naltrexone for the treatment of obesity: review and update
Michael William Lee et al.
EXPERT OPINION ON PHARMACOTHERAPY (2009)
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
John B. Buse et al.
LANCET (2009)
Enhanced Weight Loss With Pramlintide/Metreleptin: An Integrated Neurohormonal Approach to Obesity Pharmacotherapy
Eric Ravussin et al.
OBESITY (2009)
Cancer Incidence and Mortality After Gastric Bypass Surgery
Ted D. Adams et al.
OBESITY (2009)
Antiobesity Surgery in Sweden From 1980 to 2005 A Population-Based Study With A Focus on Mortality
Richard Marsk et al.
ANNALS OF SURGERY (2008)
Identification of the acyltransferase that octanoylates ghrelin, an appetite-stimulating peptide hormone
Jing Yang et al.
CELL (2008)
Ghrelin modulates brain activity in areas that control appetitive behavior
Saima Malik et al.
CELL METABOLISM (2008)
Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity
Steve R. Smith et al.
DIABETES CARE (2008)
Efficacy and Safety of Rimonabant for Improvement of Multiple Cardiometabolic Risk Factors in Overweight/Obese patients Pooled 1-year data from the Rimonabant in Obesity (RIO) program
Luc Van Gaal et al.
DIABETES CARE (2008)
Sibutramine: current status as an anti-obesity drug and its future perspectives
Bikash Sharma et al.
EXPERT OPINION ON PHARMACOTHERAPY (2008)
The effects of pancreatic polypeptide on locomotor activity and food intake in mice
Y-L Liu et al.
INTERNATIONAL JOURNAL OF OBESITY (2008)
The satiety hormone peptide YY as a regulator of appetite
R. P. Vincent et al.
JOURNAL OF CLINICAL PATHOLOGY (2008)
Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity
Brian M. Smith et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Lorcaserin, a novel selective human 5-Hydroxytryptamine2C agonist:: In vitro and in vivo pharmacological characterization
William J. Thomsen et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial
Arne Astrup et al.
LANCET (2008)
Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet
Iris Shai et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Inhibition of ghrelin O-acyltransferase (GOAT) by octanoylated pentapeptides
Jing Yang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Gastric banding for the treatment of type 2 diabetes mellitus in morbidly obese
Anthony Brancatisano et al.
SURGERY FOR OBESITY AND RELATED DISEASES (2008)
Long term pharmacotherapy for obesity and overweight: updated meta-analysis
Diana Rucker et al.
BMJ-BRITISH MEDICAL JOURNAL (2007)
The obesity-associated FTO gene encodes a 2-oxoglutarate-dependent nucleic acid demethylase
Thomas Gerken et al.
SCIENCE (2007)
Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: A multinational, randomized, open-label, two-period, crossover noninferiority trial
Anthony H. Barnett et al.
CLINICAL THERAPEUTICS (2007)
PYY modulation of cortical and hypothalamic brain areas predicts feeding behaviour in humans
Rachel L. Batterham et al.
NATURE (2007)
Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass
Carel W. le Roux et al.
ANNALS OF SURGERY (2007)
Long-term persistence with orlistat and sibutramine in a population-based cohort
R. Padwal et al.
INTERNATIONAL JOURNAL OF OBESITY (2007)
Comparative long-term mortality after laparoscopic adjustable gastric banding versus nonsurgical controls
Luca Busetto et al.
SURGERY FOR OBESITY AND RELATED DISEASES (2007)
Long-term mortality after gastric bypass surgery
Ted D. Adams et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Effects of bariatric surgery on mortality in Swedish obese subjects
Lars Sjostrom et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: A phase 2, randomized, placebo-controlled, dose-escalation study
Louis Aronne et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Efficacy and safety of incretin therapy in type 2 diabetes - Systematic review and meta-analysis
Renee E. Amori et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Weight regain in US adults who experienced substantial weight loss, 1999-2002
Edward C. Weiss et al.
AMERICAN JOURNAL OF PREVENTIVE MEDICINE (2007)
Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome
Lydia E. Kuo et al.
NATURE MEDICINE (2007)
Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes
Dennis Kim et al.
DIABETES CARE (2007)
Variation in FTO contributes to childhood obesity and severe adult obesity
Christian Dina et al.
NATURE GENETICS (2007)
Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults
Ira Gantz et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Distribution of peripherally injected peptide YY ([I-125] PYY (3-36)) and pancreatic polypeptide ([I-125] hPP) in the CNS: enrichment in the area postrema
Dumont Yvan et al.
JOURNAL OF MOLECULAR NEUROSCIENCE (2007)
Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial
K. Wynne et al.
INTERNATIONAL JOURNAL OF OBESITY (2006)
Differential hypothalamic neuronal activation following peripheral injection of GLP-1 and oxyntomodulin in mice detected by manganese-enhanced magnetic resonance imaging
Owais B. Chaudhri et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
A self-regulation program for maintenance of weight loss
Rena R. Wing et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Physiological evidence for the involvement of peptide YY in the regulation of energy homeostasis in humans
Yan Guo et al.
OBESITY (2006)
Critical role for peptide YY in protein-mediated satiation and body-weight regulation
Rachel L. Batterham et al.
CELL METABOLISM (2006)
Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus
R. E. Ratner et al.
DIABETES OBESITY & METABOLISM (2006)
Anti-ghrelin Spiegelmer NOX-B11 inhibits neurostimulatory and orexigenic effects of peripheral ghrelin in rats
P. Kobelt et al.
GUT (2006)
Ghrelin neutralization by a ribonucleic acid-SPM ameliorates obesity in diet-induced obese mice
LP Shearman et al.
ENDOCRINOLOGY (2006)
Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety
CM Borg et al.
BRITISH JOURNAL OF SURGERY (2006)
Safety of drug therapies used for weight loss and treatment of obesity
LL Ioannides-Demos et al.
DRUG SAFETY (2006)
Attenuated peptide YY release in obese subjects is associated with reduced satiety
CW le Roux et al.
ENDOCRINOLOGY (2006)
Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters
CW le Roux et al.
ANNALS OF SURGERY (2006)
Factors promoting and ameliorating the development of obesity
BE Levin
PHYSIOLOGY & BEHAVIOR (2005)
Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects - A double-blind, randomized, controlled trial
K Wynne et al.
DIABETES (2005)
The inhibitory effects of peripheral administration of peptide YY3-36 and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway
CR Abbott et al.
BRAIN RESEARCH (2005)
A potential decline in life expectancy in the United States in the 21st century
SJ Olshansky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
A novel growth hormone secretagogue-1a receptor antagonist that blocks ghrelin-induced growth hormone secretion but induces increased body weight gain
HA Halem et al.
NEUROENDOCRINOLOGY (2005)
Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects
E Näslund et al.
BRITISH JOURNAL OF NUTRITION (2004)
Infusion of the amylin antagonist AC 187 into the area postrema increases food intake in rats
A Mollet et al.
PHYSIOLOGY & BEHAVIOR (2004)
Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure
LL Baggio et al.
GASTROENTEROLOGY (2004)
The NPY system in stress, anxiety and depression
M Heilig
NEUROPEPTIDES (2004)
Plasma ghrelin levels and hunger scores in humans initiating meals voluntarily without time- and food-related cues
DE Cummings et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2004)
Feeding response to ghrelin agonist and antagonist in lean and obese Zucker rats
B Beck et al.
LIFE SCIENCES (2004)
Peripheral oxyntomodulin reduces food intake and body weight gain in rats
CL Dakin et al.
ENDOCRINOLOGY (2004)
Gastrointestinal satiety signals - III. Glucagon-like peptide 1, oxyntomodulin, peptide YY, and pancreatic polypeptide
S Stanley et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2004)
Acute effects of PYY3-36 on food intake and hypothalamic neuropeptide expression in the mouse
BG Challis et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2003)
Oxyntomodulin suppresses appetite and reduces food intake in humans
MA Cohen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Inhibition of food intake in obese subjects by peptide YY3-36
RL Batterham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Minireview: Human obesity - Lessons from monogenic disorders
S O'Rahilly et al.
ENDOCRINOLOGY (2003)
Pancreatic polypeptide reduces appetite and food intake in humans
RL Batterham et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Antagonism of ghrelin receptor reduces food intake and body weight gain in mice
A Asakawa et al.
GUT (2003)
A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity
GA Bray et al.
OBESITY RESEARCH (2003)
Characterization of the effects of pancreatic polypeptide in the regulation of energy balance
A Asakawa et al.
GASTROENTEROLOGY (2003)
Vagotomy dissociates short- and long-term controls of circulating ghrelin
DL Williams et al.
ENDOCRINOLOGY (2003)
The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to intra-abdominal fat
DJ Nieves et al.
DIABETES (2003)
Leptin and insulin action in the central nervous system
D Porte et al.
NUTRITION REVIEWS (2002)
Ghrelin stimulates GH but not food intake in arcuate nucleus ablated rats
H Tamura et al.
ENDOCRINOLOGY (2002)
Gut hormone PYY3-36 physiologically inhibits food intake
RL Batterham et al.
NATURE (2002)
Ghrelin causes hyperphagia and obesity in rats
AM Wren et al.
DIABETES (2001)
Chronic central infusion of ghrelin increases hypothalamic neuropeptide Y and agouti-related protein mRNA levels and body weight in rats
J Kamegai et al.
DIABETES (2001)
Bupropion for weight loss: An investigation of efficacy and tolerability in overweight and obese women
KM Gadde et al.
OBESITY RESEARCH (2001)
A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans
DE Cummings et al.
DIABETES (2001)
Impact of overweight on the risk of developing common chronic diseases during a 10-year period
AE Field et al.
ARCHIVES OF INTERNAL MEDICINE (2001)
The anorectic effect of a chronic peripheral infusion of amylin is abolished in area postrema nucleus of the solitary tract (AP/NTS) lesioned rats
TA Lutz et al.
INTERNATIONAL JOURNAL OF OBESITY (2001)
Circulating Ghrelin levels are decreased in human obesity
M Tschöp et al.
DIABETES (2001)
The-pole of gastrointestinal vagal afferents in the control of food intake: Current prospects
GJ Schwartz
NUTRITION (2000)
Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors
TM Loftus et al.
SCIENCE (2000)
Share Paper
